Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
BVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.90 - $14.38
Previous CloseN/A
Volume116.12K
Average Volume (3M)358.65K
Market Cap
$772.73M
Enterprise Value$1.04B
Total Cash (Recent Filing)$41.58M
Total Debt (Recent Filing)$27.34M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 13, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding66,156,870
10 Day Avg. Volume375,778
30 Day Avg. Volume358,653
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.38
Price to Cash Flow (P/CF)10.20
P/FCF Ratio10.30
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.81
Enterprise Value/Ebitda35.91
Forecast
1Y Price Target
$16.00Price Target Upside75.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bioventus News
PremiumCompany Announcements
Bioventus Earnings Call: Strong Growth & 2025 Outlook
PremiumCompany Announcements
Bioventus Reports Strong 2024 Financial Performance
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBVS posted a strong Q4, beating revenue, adj. EBITDA, and pro forma EPS expectations with significant improvements in its business units.
Growth StrategyThe planned divestiture of the Rehab business should allow Bioventus to refocus on higher growth, higher margin opportunities.
Investment And CompetitivenessBVS has the financial breathing room to invest in commercial and R&D activities, which helps the company remain competitive.
Bears Say
Debt ConcernsBioventus still has a significant amount of debt on its balance sheet, which could limit strategic uses of capital.
Revenue ChallengesQ1/H1 organic revenues should be more challenged given two fewer selling days in the Q1, pull-forward of HA orders from the Q1/25 to Q4/24, and continued BGS distributor choppiness for a couple more quarters.
Short-term Growth OutlookBVS expects some weaker growth in its BGS business over the next couple of quarters as it works to onboard new distributors.
---
Ownership Overview
32.14% Insiders
7.87% Mutual Funds
0.18% Other Institutional Investors
51.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $3.90 and its highest was $14.38 in the past 12 months.
What is Bioventus’s market cap?
Bioventus’s market cap is $772.73M.
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is May 13, 2025 which is in 47 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Mar 11, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.083 by $0.067.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is 0.02.
How many shares outstanding does Bioventus have?
Bioventus has 66,156,870 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.15 in its last earnings report, beating expectations of $0.083. Following the earnings report the stock price went up 23.288%.
Which hedge fund is a major shareholder of Bioventus?
Currently, no hedge funds are holding shares in BVS
---
Bioventus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (75.44% Upside)
$16.00 (75.44% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 255.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
77.43%
12-Months-Change
Fundamentals
Return on Equity
-20.86%
Trailing 12-Months
Asset Growth
-10.23%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
---
BVS Company Deck
---
BVS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Bioventus demonstrated strong financial performance with significant revenue growth, improved profitability, and successful debt reduction. Challenges included a flat performance in Restorative Therapies and price sensitivity in the GELSYN product. Overall, the positives outweigh the negatives, with a promising outlook for 2025.Read More>---
BVS Stock 12 Month Forecast
Average Price Target
$16.00
▲(75.44% Upside)
Technical Analysis
Best Analysts Covering BVS
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+45.30%
reiterated a buy rating 16 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +45.30% per trade.
---